| Ayaaz A Habibullah, MD | |
|
900 W Nifong Blvd Ste 101, Columbia, MO 65203-4469 | |
| (573) 499-9009 | |
| Not Available |
| Full Name | Ayaaz A Habibullah |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 8 Years |
| Location | 900 W Nifong Blvd Ste 101, Columbia, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063932002 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 125071326 (Illinois) | Secondary |
| 207Q00000X | Family Medicine | 2020019624 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Elara Caring | Jefferson city, MO | Home health agency |
| Boone Hospital Center | Columbia, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boone Physician Services Llc | 6507090644 | 226 |
News Archive
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.
HAL Allergy today announced that it has filed marketing authorization applications (MAA) for PURETHAL(R) Mites and SUBLIVAC(R) FIX Grasses, Trees, and Mites (incl. homologous group products) at the Paul-Ehrlich-Institute, the regulatory authority in Germany.
UK regulators have approved Europe's first clinical trial of a monoclonal antibody produced from genetically modified plants. This landmark decision sets the stage for the testing, in humans, of an anti-HIV product made from genetically modified tobacco plants. It will open the door for trials of additional plant-derived medicines treating a range of diseases.
A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, "Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?"
› Verified 8 days ago
| Entity Name | Boone Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760893259 PECOS PAC ID: 6507090644 Enrollment ID: O20131003000535 |
News Archive
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.
HAL Allergy today announced that it has filed marketing authorization applications (MAA) for PURETHAL(R) Mites and SUBLIVAC(R) FIX Grasses, Trees, and Mites (incl. homologous group products) at the Paul-Ehrlich-Institute, the regulatory authority in Germany.
UK regulators have approved Europe's first clinical trial of a monoclonal antibody produced from genetically modified plants. This landmark decision sets the stage for the testing, in humans, of an anti-HIV product made from genetically modified tobacco plants. It will open the door for trials of additional plant-derived medicines treating a range of diseases.
A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, "Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?"
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ayaaz A Habibullah, MD 900 W Nifong Blvd Ste 101, Columbia, MO 65203-4469 Ph: (573) 499-9009 | Ayaaz A Habibullah, MD 900 W Nifong Blvd Ste 101, Columbia, MO 65203-4469 Ph: (573) 499-9009 |
News Archive
The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.
HAL Allergy today announced that it has filed marketing authorization applications (MAA) for PURETHAL(R) Mites and SUBLIVAC(R) FIX Grasses, Trees, and Mites (incl. homologous group products) at the Paul-Ehrlich-Institute, the regulatory authority in Germany.
UK regulators have approved Europe's first clinical trial of a monoclonal antibody produced from genetically modified plants. This landmark decision sets the stage for the testing, in humans, of an anti-HIV product made from genetically modified tobacco plants. It will open the door for trials of additional plant-derived medicines treating a range of diseases.
A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, "Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?"
› Verified 8 days ago
Nicholas Michael Lefevre, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 551 E Southampton Dr, Columbia, MO 65201 Phone: 573-884-7733 Fax: 573-882-6228 | |
Richelle J Koopman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2325 Smiley Ln, Columbia, MO 65202 Phone: 573-884-8980 Fax: 573-884-0040 | |
Susan Z. John, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 909 Hitt St, Columbia, MO 65211 Phone: 573-882-7481 Fax: 573-882-5370 | |
Dr. Christopher Joseph Sporleder, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 | |
Dr. Christopher D. Farmer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 S Keene St, Columbia, MO 65201 Phone: 573-443-2402 Fax: 573-443-0574 | |
David D Cravens, MD, MSPH, CMD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: One Hospital Drive, Columbia, MO 65201 Phone: 573-884-7733 Fax: 573-884-5559 | |
Dr. Shannon Rhea Sitzmann, DNP, APRN, FNP-BC Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2900 Trimble Rd Ste 107, Columbia, MO 65201 Phone: 573-818-3067 |